Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
April 11, 2025
Resolving Inflammation Without Immunosuppression
Most available treatments used to treat inflammation suppress the immune system which can lead to a heightened risk of serious safety issues. Inflammation resolution strategies seek to provide both anti-inflammatory and pro-resolving activity without suppressing the immune system.
Harnessing the Melanocortin System to Resolve Inflammation
SynAct harnesses the melanocortin system to stimulate both anti-inflammatory and inflammation resolution mechanisms to resolve excessive inflammation safely without suppressing the immune system’s ability to respond to new infections or injuries.
Resomelagon (AP1189)
An Oral Selective Melanocortin Agonist
Our lead drug candidate resomelagon (AP1189) is a once-daily oral selective melanocortin agonist that selectively stimulates melanocortin receptors to help the body resolve inflammation. Resomelagon (AP1189) is being evaluated in rheumatoid arthritis (RA), idiopathic membranous nephropathy (iMN) and respiratory insufficiency caused by viruses like COVID-19.
-
May 27, 2025 RegulatoryBulletin from the annual general meeting 2025 in SynAct Pharma AB
-
May 27, 2025 RegulatorySynAct Pharma publishes Q1 2025 interim results
-
May 12, 2025 Non RegulatorySynAct receives Issue Notification and Patent Term Adjustment for US patent covering resomelagon (AP1189) combination therapy
A MESSAGE FROM OUR CEO
”Having extended patent protection until 2042 is pivotal for ensuring resomelagon’s value for us and future potential partners.”